ASHLEY MURILLO: Open Payments
NPI 1881373397 · CONVERSE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$790 in 27 payments from 11 companies in 2025. Trend: 2023 $305 · 2024 $1,878 · 2025 $790
Food & beverage: $790
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 6 | $189 |
| Abbott Laboratories | 2 | $174 |
| Sumitomo Pharma America, Inc. | 3 | $142 |
| PFIZER INC. | 5 | $99 |
| Amgen Inc. | 3 | $48 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| Novo Nordisk Inc | 1 | $24 |
| ABBVIE INC. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $17 |
Products named: CARDIOMEMS, GEMTESA, ZEPBOUND, MOUNJARO, ELIQUIS, OTEZLA, NURTEC ODT, XIFAXAN.
Industry payments across TX — which companies pay providers there.
